Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

TLSA

Tiziana Life Sciences Ltd

Jan 16 • 04:00PM ET

1.68

+0.23 15.86 %

Healthcare • Biotechnology • United Kingdom • NASD

Jan 16, 2:50 PMTiziana Life Sciences closes an oversubscribed $8.8M registered direct offering of 7.04M shares with $1.50 warrants to fund completion of Phase 2 na-SPMS and MSA trials, upsized from the earlier $8M, 6.4M-share pricing.

Peers: BMY MRK PFE GILD AMGN VRTX REGN BIIB INCY NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.11	Insider Own	46.55%	Shs Outstand	118.82M	Perf Week	17.48%
Market Cap	199.67M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	0.00%	Shs Float	63.52M	Perf Month	8.39%
Enterprise Value	192.53M	PEG	-	EPS next Q	-	Inst Own	3.38%	Short Float	2.57%	Perf Quarter	-16.83%
Income	-12.84M	P/S	-	EPS this Y	-65.46%	Inst Trans	-6.24%	Short Ratio	5.35	Perf Half Y	8.39%
Sales	0.00M	P/B	21.70	EPS next Y	-11.11%	ROA	-93.18%	Short Interest	1.63M	Perf YTD	12.75%
Book/sh	0.08	P/C	27.54	EPS next 5Y	-	ROE	-232.31%	52W High	2.60 -35.38%	Perf Year	113.31%
Cash/sh	0.06	P/FCF	-	EPS past 3/5Y	22.52% -10.24%	ROIC	-139.58%	52W Low	0.63 166.58%	Perf 3Y	177.45%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.08% 9.33%	Perf 5Y	-37.31%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	14.38%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.72	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.69	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.72	EPS Q/Q	-6.87%	SMA20	12.41%	Beta	0.19	Target Price	8.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	2.88%	Rel Volume	5.27	Prev Close	1.45
Employees	9	LT Debt/Eq	0.00	Earnings	Oct 01	SMA200	1.35%	Avg Volume	305.04K	Price	1.68
IPO	Nov 20, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1,517,248	Change	15.86%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-20	Initiated	B. Riley Securities	Buy	$8
Dec-17-18	Initiated	Laidlaw	Buy

Jan-16-26 02:45PM	Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) +15.86%
07:00AM	Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million (GlobeNewswire)
Jan-09-26 07:00AM	Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco (GlobeNewswire)
Dec-30-25 08:15AM	Tiziana Life Sciences files annual safety report for intranasal foralumab (TipRanks)
Dec-29-25 08:00AM	Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA (GlobeNewswire)
11:00AM	Loading…
Dec-19-25 11:00AM	Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman (GlobeNewswire) +5.56%
Dec-17-25 10:00AM	Tiziana Life Sciences to Ring the Closing Bell at Nasdaq (GlobeNewswire) -5.81%
08:45AM	Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial (GlobeNewswire)
Dec-15-25 03:07PM	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire) -10.67%
07:30AM	Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering (GlobeNewswire)
Dec-12-25 02:10PM	Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial (GlobeNewswire)
Dec-02-25 07:00AM	Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company (GlobeNewswire)
Nov-25-25 08:30AM	Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program (GlobeNewswire) +5.20%
Nov-13-25 08:30AM	Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference (GlobeNewswire) -7.30%
Oct-29-25 07:00AM	Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy (GlobeNewswire)
08:30AM	Loading…
Sep-30-25 08:30AM	Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia (GlobeNewswire)
Sep-25-25 08:30AM	Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody (GlobeNewswire) +5.08%
Sep-24-25 08:30AM	Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress (GlobeNewswire) +11.93%
Sep-23-25 07:24PM	Tiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord Injury (Insider Monkey)
Sep-15-25 08:00AM	Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury (GlobeNewswire)
Sep-09-25 10:04AM	Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer (GlobeNewswire) +14.20%
Sep-05-25 08:30AM	Tiziana Life Sciences Announces Purchase of Shares by Chairman (GlobeNewswire) +5.06%
Aug-14-25 08:30AM	Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy (GlobeNewswire) -6.10%
Aug-11-25 09:00AM	FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy (GlobeNewswire) +11.82%
Jul-21-25 07:00AM	Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient (GlobeNewswire)
Jun-13-25 10:30AM	Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center (GlobeNewswire) +9.15%
08:30AM	Tiziana Life Sciences to Present at the Bio International Convention (GlobeNewswire)
May-23-25 07:00AM	Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease (GlobeNewswire) +15.33%
May-15-25 08:00AM	Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease (GlobeNewswire)
May-12-25 07:00AM	Tiziana Life Sciences Announces Purchase of Shares by Chairman (GlobeNewswire)
07:00AM	Loading…
May-09-25 07:00AM	Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab (GlobeNewswire)
May-06-25 07:00AM	Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis (GlobeNewswire) +22.95%
Apr-30-25 05:39AM	Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025 (Insider Monkey) +9.68%
Apr-24-25 11:14AM	Dosing begins in Tiziana Life Sciences trial of foralumab for na-SPMS (Clinical Trials Arena) +9.92%
Apr-23-25 07:00AM	Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial (GlobeNewswire) +12.93%
Apr-02-25 08:00AM	Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial (GlobeNewswire)
Mar-26-25 07:58AM	Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis (Clinical Trials Arena)
Mar-25-25 08:00AM	Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial (GlobeNewswire) +13.89%
Mar-17-25 08:00AM	Tiziana Life Sciences to Present at the 37th Annual Roth Conference (GlobeNewswire)
Mar-14-25 08:30AM	Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule (GlobeNewswire) +6.08%
Mar-04-25 08:00AM	Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial (GlobeNewswire)
Mar-02-25 09:25AM	Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-27-25 08:00AM	Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury (GlobeNewswire) +15.31%
Feb-25-25 08:00AM	Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter (GlobeNewswire) +6.07%
Feb-21-25 08:00AM	Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC (GlobeNewswire) -8.90%
Feb-18-25 08:00AM	Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program (GlobeNewswire) +11.07%
Feb-11-25 09:15AM	Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease (GlobeNewswire)
Jan-23-25 03:00PM	Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3 (GlobeNewswire) +11.06%
08:54AM	Tiziana Life Sciences not to engage in capital raising activities for the immediate future (GlobeNewswire)
Jan-22-25 04:05PM	Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab (GlobeNewswire) +8.51%
Jan-10-25 08:00AM	Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3 (GlobeNewswire) +14.13%
Jan-08-25 07:00AM	Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease (GlobeNewswire)
Dec-17-24 07:00AM	Tiziana Life Sciences Announces First Patient with Moderate Alzheimer's Disease Dosed with Intranasal Foralumab (GlobeNewswire) +6.50%
Dec-05-24 07:07AM	Tiziana Life Sciences expands Phase 2 trial for non-active SPMS (TipRanks)
Dec-04-24 07:00AM	Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers (GlobeNewswire) +12.09%
Nov-20-24 07:28AM	Tiziana Life Sciences Secures ALS Trial Funding (TipRanks)
Nov-19-24 07:00AM	Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association (GlobeNewswire)
Nov-01-24 01:00PM	Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data (GlobeNewswire)
Oct-30-24 10:29PM	Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million (GlobeNewswire) +15.69% -17.37%
08:30AM	Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study (GlobeNewswire)
Oct-26-24 05:49PM	Tiziana Life Sciences Plans Share Sale with Jefferies (TipRanks)
Oct-19-24 05:27PM	Tiziana Life Sciences Advances with Promising Drug Trials (TipRanks)
Sep-19-24 07:00AM	Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer's Disease (GlobeNewswire)
Aug-19-24 07:00AM	Tiziana Life Sciences Appoints New Chief Executive Officer (GlobeNewswire) -5.79%
Aug-14-24 07:00AM	Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule (GlobeNewswire) -19.85%
Aug-10-24 02:00PM	The 3 Best EV Stocks to Buy in August 2024 (InvestorPlace)
Jul-24-24 07:00AM	Tiziana Life Sciences Granted FDA Fast Track Designation (GlobeNewswire) +11.10%
Jun-28-24 11:01AM	Tiziana Receives $3.4 Million in Non-Dilutive Funding (GlobeNewswire)
07:53AM	Tiziana Life Sciences adds to treasury with $3.4 million in non-dilutive funding (News Direct)
Jun-26-24 07:00AM	Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab (GlobeNewswire)
Jun-11-24 08:45AM	Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises (GlobeNewswire)
08:00AM	FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis (GlobeNewswire)
Jun-06-24 09:00AM	Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab (GlobeNewswire)
Jun-04-24 09:00AM	Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab (GlobeNewswire)
May-30-24 07:00AM	Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research (GlobeNewswire)
May-13-24 07:00AM	Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab (GlobeNewswire)
Apr-25-24 10:00AM	Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab (GlobeNewswire) +6.45%
Apr-23-24 09:32AM	Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program (MT Newswires)
07:00AM	Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program (GlobeNewswire)
Apr-22-24 07:00AM	Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program (GlobeNewswire) +13.15%
Apr-19-24 07:00AM	Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today (GlobeNewswire)
Apr-18-24 07:00AM	Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology (GlobeNewswire) +24.76%
Apr-11-24 07:00AM	Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology (GlobeNewswire)
Mar-05-24 07:00AM	Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease (GlobeNewswire) +9.60%
Jan-08-24 07:00AM	Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients (GlobeNewswire) -6.79%
Jan-05-24 09:30AM	Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 (GlobeNewswire)
07:00AM	Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation (GlobeNewswire)
Dec-19-23 07:00AM	Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis (GlobeNewswire) +5.45%
Dec-04-23 07:09AM	Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar (GlobeNewswire)
Nov-30-23 07:00AM	Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis (GlobeNewswire)
Nov-01-23 07:00AM	Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023 (GlobeNewswire)
Oct-20-23 05:20AM	TLSA: Six Month SPMS Results (Zacks)
Oct-18-23 07:00AM	Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment (GlobeNewswire)
Oct-17-23 03:27AM	Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial (News Direct) -14.00%
Oct-16-23 07:00AM	Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab (GlobeNewswire) +6.25%
Oct-13-23 07:00AM	Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS) (GlobeNewswire) +8.14%
Oct-11-23 07:00AM	Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress (GlobeNewswire)
Sep-26-23 07:00AM	Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis (GlobeNewswire)
Sep-12-23 08:19AM	Tiziana Life Sciences' Alzheimer's treatment validated in new study (News Direct)
Sep-08-23 07:00AM	Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer's. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLSA

Tiziana Life Sciences Ltd

Upgrade your FINVIZ experience